Project Grant R01CA303334
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $718K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $645,102 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026, through June 30, 2031. The award funds fundamental research investigating the molecular mechanisms governing WEE1 kinase's transition between functioning as a cell cycle checkpoint enzyme and as a phosphorylation substrate. The research addresses a critical gap in cell cycle...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through July 31, 2032. The award supports research into new approaches to targeting cell cycle proteins for cancer treatment, specifically addressing limitations of current cyclin-dependent kinase (CDK) inhibitors. The project focuses on three critical therapeutic...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $170,394 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2026, through June 30, 2028. This award supports biomedical research training and workforce development in cancer biology, specifically funding postdoctoral research investigating the epigenetic mechanisms underlying neuroendocrine lineage carcinomas. The research focuses on defining...
- Federal Grant Award Summary Award Overview: The National Cancer Institute (NCI) awarded Harvard Medical School a Project Grant of $237,023 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research through February 28, 2029. The award funds development of high-throughput technological tools to track the fate and dynamics of prematurely terminated transcripts in cancer cells, with performance conducted in Boston, Massachusetts. Research Deliverables: The...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $110,190 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective December 27, 2025 through June 30, 2028. The award supports biomedical training and research development in cancer biology, specifically focused on unraveling the mechanisms of neoantigen vaccine-induced epitope spreading (ES)—a phenomenon in which vaccine-primed tumor cell destruction...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $737,086 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award supports translational research to identify and validate novel therapeutic targets for translocation renal cell carcinoma (TRCC), an aggressive cancer subtype currently lacking approved targeted therapies. The research delivers two primary products:...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $683,075 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective March 24, 2026 through February 28, 2031. The award supports basic research investigating the mitotic function of the protein 53BP1 and its negative regulator TIRR in maintaining genome stability and preventing cancer-related chromosomal abnormalities. The research project,...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded Dana-Farber Cancer Institute, Inc. a $979,000 Project Grant effective August 1, 2025, through May 31, 2030, under the Biomedical Research and Research Training program (CFDA 93.859). The award funds research to advance Nuclear Magnetic Resonance (NMR) technology for mechanistic biology applications. The project delivers strategic innovations designed to expand NMR's capabilities for protein structure...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $721,653 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded June 5, 2026, with completion scheduled for May 31, 2031. The award funds research into protein O-mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade gliomas (PLGGs), which represent the most frequent solid tumors in childhood. The institute will...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.602M Project Grant award from the National Institute of Environmental Health Sciences under the Medical Library Assistance program (CFDA 93.879) effective September 1, 2025, through August 31, 2029. The project focuses on developing computational methods for analyzing multiplex immunofluorescence (MIF) imaging data of the tumor microenvironment. The research leverages a clinically validated MIF dataset encompassing...